Weight reduction with Mounjaro
Mounjaro is a dual-acting agonist (GIP + GLP-1) that shows significantly more effective weight loss than pure GLP-1 receptor drugs such as semaglutide (e.g., Wegovy or Ozempic).
In clinical trials, over 70% of participants on 10 mg and 15 mg doses lost ≥ 20% of their body weight within 72 weeks, with an average weight reduction of 20.2% (compared to 13.7% with semaglutide).
Even after three years, approximately 20% of the weight loss remained stable.